BBIO stock news · BridgeBio Pharma

Stories about BridgeBio Pharma (BBIO) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for BBIO

Follow BridgeBio Pharma (BBIO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Oct 30, 2026, 6:51 PM ET · Opinion
Morgan Stanley kept its positive rating on BridgeBio Pharma and raised the price target from $87 to $88.
Good for BBIO
Morgan Stanley kept its positive rating on BridgeBio Pharma and lifted its target slightly. This is a small positive signal, but the note reports no new company results.
Sep 1, 2026, 5:06 AM ET · Deal
Nine additional pharmaceutical partnerships announced by Trump increase total agreements to 26 — RFK Jr. shares insights on 'deeply emotional' discussions with the President.
Bad for BBIO
BridgeBio is named among companies required to offer outpatient drug discounts, implying reduced U.S. pricing and revenue pressure.
Aug 17, 2026, 10:05 AM ET · Market
BridgeBio Pharma, Inc. enters into a significant definitive agreement (BBIO).
Neutral
BridgeBio Pharma, Inc. has filed a Form 8-K indicating its entry into a material definitive agreement, which is likely to have significant implications for its business strategy and financial outlook. This development is expected to be positively received by the market as it suggests potential growth opportunities.